STERIS plc (NYSE:STE) Position Raised by Foster Victor Wealth Advisors LLC

Foster Victor Wealth Advisors LLC boosted its position in STERIS plc (NYSE:STE) by 10.1% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 68,126 shares of the medical equipment provider’s stock after purchasing an additional 6,266 shares during the period. Foster Victor Wealth Advisors LLC owned approximately 0.07% of STERIS worth $14,281,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Ashton Thomas Securities LLC acquired a new stake in shares of STERIS in the third quarter valued at $25,000. Central Pacific Bank Trust Division bought a new stake in STERIS in the third quarter worth about $28,000. Quarry LP acquired a new stake in STERIS in the 3rd quarter valued at about $67,000. Asset Dedication LLC boosted its position in shares of STERIS by 54.8% during the 3rd quarter. Asset Dedication LLC now owns 291 shares of the medical equipment provider’s stock valued at $71,000 after purchasing an additional 103 shares in the last quarter. Finally, R Squared Ltd acquired a new position in shares of STERIS in the 4th quarter worth approximately $78,000. 94.69% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. Piper Sandler raised shares of STERIS from a “neutral” rating to an “overweight” rating and increased their target price for the company from $230.00 to $260.00 in a research note on Thursday, October 24th. StockNews.com downgraded STERIS from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, October 29th. JMP Securities restated a “market outperform” rating and issued a $265.00 target price on shares of STERIS in a report on Monday, November 18th. Stephens reaffirmed an “overweight” rating and set a $260.00 target price on shares of STERIS in a research report on Thursday, November 7th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of STERIS in a research report on Friday, November 8th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $262.50.

STERIS Stock Performance

Shares of STERIS stock opened at $221.28 on Wednesday. STERIS plc has a 12 month low of $197.82 and a 12 month high of $248.24. The company has a quick ratio of 1.55, a current ratio of 2.41 and a debt-to-equity ratio of 0.33. The stock has a market cap of $21.84 billion, a PE ratio of 50.52 and a beta of 0.84. The business has a fifty day simple moving average of $211.74 and a 200-day simple moving average of $224.80.

STERIS (NYSE:STE) last announced its quarterly earnings data on Wednesday, November 6th. The medical equipment provider reported $2.14 EPS for the quarter, topping analysts’ consensus estimates of $2.12 by $0.02. The firm had revenue of $1.33 billion during the quarter, compared to analyst estimates of $1.33 billion. STERIS had a return on equity of 13.78% and a net margin of 8.02%. The business’s quarterly revenue was up 7.3% compared to the same quarter last year. During the same period last year, the company posted $2.03 EPS. On average, sell-side analysts anticipate that STERIS plc will post 9.11 EPS for the current fiscal year.

STERIS Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, March 21st. Shareholders of record on Thursday, February 20th will be given a $0.57 dividend. This represents a $2.28 dividend on an annualized basis and a yield of 1.03%. STERIS’s payout ratio is 52.05%.

Insider Buying and Selling at STERIS

In other news, SVP Cary L. Majors sold 1,682 shares of the firm’s stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $217.32, for a total transaction of $365,532.24. Following the completion of the sale, the senior vice president now directly owns 11,372 shares of the company’s stock, valued at $2,471,363.04. This trade represents a 12.88 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 1.14% of the company’s stock.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.